Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Shrugs Off Xofigo Sales Pressure From Study Halt

Executive Summary

Amid turmoil at Bayer's R&D unit, the company revealed that a Phase III trial of Xofigo had thrown up a safety issue for the product. Bayer insists peaks sales will be unaffected, but what had been a large potential new patient population now looks unlikely.

You may also be interested in...



Bayer Confident It Can Cope With Patent Cliff Pain

The German major noted that the effects of the losses of patent protection on Xarelto and Eylea are still about five years down the line and it expects to be able to soften the blow with some future big-earners from the pipeline and more external deals.

Bayer Sees Room For Third-To-Market Darolutamide In Prostate Cancer

ASCO GU: Darolutamide is important for the company's oncology portfolio, but does it have enough to compete against J&J's Erleada and Pfizer/Astellas' Xtandi?

Interview: Joerg Moeller, Bayer Development Chief, On R&D Consolidation

Scrip caught up with Joerg Moeller, head of development at Bayer Pharmaceuticals, during the company's annual media day. Soon to take leadership of the German group's entire R&D organization, he talked about Bayer's R&D strategy and how the pharma industry will need to work with other healthcare stakeholders more collaboratively.

Topics

Related Companies

UsernamePublicRestriction

Register

SC099981

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel